En esta página
01PTCT precio
02Instantánea
03Gráfico
05Acerca de
06Rendimiento
07Valoración y ratios
14Ganancias
15Fundamentales Completos
16Estados Financieros
17Propietarios institucionales (13F)
18Activistas y propietarios del %+ 5
19Informantes de la empresa
20Propiedad de ETFs
21Consenso
22Pares
25Señales de trading
26Mis Métricas
PTCT PTC Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Jul 30, 2026
$63,46
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$61,23mínimo 52 semanas
$90,87máximo 52 semanas
Capitalización Bursátil (MRQ)
$5.29B
P/E (TTM)
-117.5
BPA (TTM)
$-0.54
Ingresos (TTM)
$1.01B
tus insignias
Rango 52S
$61–$91
Calificación del Analista
BUY
Precio Objetivo
$102
P/E
-117.5
ROE
20.6%
Margen de Beneficio Neto
-3.8%
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
PTCT Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$63.46
Capitalización Bursátil (MRQ)
$5.29B
P/E (TTM)
-117.5
BPA (TTM)
$-0.54
Ingresos (TTM)
$1.01B
ROE (TTM)
20.6%
Deuda/Capital (MRQ)
-3.6
Rango 52S
$61–$91
PTCT Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Acerca de PTC Therapeutics, Inc. - Common Stock Descripción general de la empresa de Wikipedia
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019.
Products
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively.
PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America.
In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
Pipeline
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth.
In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
sectorHealthcare
industriaBiotechnology
empleados991
paísUS
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$1.73B2016-12-31 → 2025-12-31
BPA$7.782019-12-31 → 2025-12-31
Flujo de caja libre$702M2016-12-31 → 2025-12-31
Margen neto-3.8%2016-12-31 → 2025-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | PTCT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E (TTM) | -117.5promedio 5A ≈-2.7 | ≈-2.7 | · | · | |
| P/S (TTM) | 5.2promedio 5A ≈3.8 | ≈3.8 | 55.0 | Infravalorado | |
| P/C (MRQ) | -32.0promedio 5A ≈481.5 | ≈481.5 | · | · | |
| EV / EBITDA (TTM) | 20.2promedio 5A ≈-5.5 | ≈-5.5 | · | · | |
| Precio / FCF (TTM) | -133.2promedio 5A ≈-10.8 | ≈-10.8 | · | · | |
| Precio / Flujo de Caja (TTM) | -173.4promedio 5A ≈-12.1 | ≈-12.1 | · | · | |
| EV / Ingresos (TTM) | 3.6promedio 5A ≈3.0 | ≈3.0 | · | · | |
| EV / FCF (TTM) | -91.9promedio 5A ≈-8.4 | ≈-8.4 | · | · | |
| Precio / Valor Contable Tangible (MRQ) | -9.3 | · | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | PTCT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Margen Operativo (TTM) | 12.5%promedio 5A ≈-25.9% | ≈-25.9% | -24.1% | De primer nivel | |
| Margen EBITDA (TTM) | 17.9%promedio 5A ≈-13.8% | ≈-13.8% | -24.1% | De primer nivel | |
| Margen antes de impuestos (TTM) | -6.6%promedio 5A ≈-43.8% | ≈-43.8% | -28.9% | De primer nivel | |
| Margen de Beneficio Neto (TTM) | -3.8%promedio 5A ≈-42.4% | ≈-42.4% | -38.1% | De primer nivel | |
| ROA (TTM) | -1.3%promedio 5A ≈-12.6% | ≈-12.6% | -27.7% | De primer nivel | |
| ROE (TTM) | 20.6%promedio 5A ≈-299.7% | ≈-299.7% | -40.8% | Débil | |
| ROIC | 1044.7%promedio 5A ≈267.1% | ≈267.1% | -37.7% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | PTCT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | -3.6promedio 5A ≈74.5 | ≈74.5 | · | · | |
| Ratio corriente (MRQ) | 3.4promedio 5A ≈2.1 | ≈2.1 | 8.3 | Baja liquidez | |
| Ratio Rápido (MRQ) | 3.2promedio 5A ≈2.0 | ≈2.0 | 3.2 | En línea | |
| Deuda a Largo Plazo / Patrimonio (MRQ) | -3.2promedio 5A ≈65.1 | ≈65.1 | · | · |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | PTCT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | 114.5%promedio 5A ≈41.2% | ≈41.2% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | 35.3%promedio 5A ≈28.3% | ≈28.3% | · | · | |
| Revenue CAGR 5Y (Ingresos CAGR 5A) | 35.4% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | PTCT | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.8promedio 5A ≈0.5 | ≈0.5 | 0.4 | De primer nivel | |
| Receivables Turnover (Rotación de Cuentas por Cobrar) | 10.2promedio 5A ≈6.8 | ≈6.8 | 9.7 | En línea | |
| Revenue / Employee (Ingresos / Empleado) | ≈$1.7M | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
105.2%
Próximo informe
Nov 02, 2026
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 5, 2026 | $0.92 | $0.43 | 116.4% |
| 31 de marzo de 2026 | $-0.03 | $-0.48 | 93.7% | |
| 31 de diciembre de 2025 | $-1.67 | $0.04 | -4460.3% | |
| 30 de septiembre de 2025 | $0.20 | $-1.40 | 114.3% | |
| 30 de junio de 2025 | $-0.83 | $-1.08 | 23.3% | |
| 31 de marzo de 2025 | $10.04 | $-0.22 | 4743.8% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Cost of Revenue | · | · | · | · | · | · | $12M | $13M | $5M | $0 | $0 | · | |
| R&D Expense | $455M | $534M | $667M | $651M | $541M | $478M | $257M | $172M | $117M | $118M | $122M | $80M | |
| SG&A Expense | $347M | $301M | $333M | $326M | $286M | $245M | $203M | $154M | $121M | $97M | $82M | $45M | |
| Operating Expenses | $864M | $1.11B | $1.38B | $1.15B | $913M | $813M | $548M | $380M | $259M | $215M | $204M | $125M | |
| Operating Income | $867M | $-303M | $-440M | $-447M | $-374M | $-432M | $-241M | $-116M | $-64M | $-132M | $-167M | $-99M | |
| Other Non-op | $-18M | $7M | $10M | $-49M | $-58M | $85M | $14M | $129.0K | $-1M | $-1M | $-465.0K | $-213.0K | |
| Pretax Income | $697M | $-363M | $-696M | $-587M | $-518M | $-403M | $-240M | $-128M | $-78M | $-142M | $-170M | $-98M | |
| Income Tax | $14M | $176.0K | $-70M | $-28M | $6M | $35M | $12M | $-29.0K | $1M | $569.0K | $485.0K | $-5M | |
| Net Income | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| EPS (Basic) | $8.58 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-2.75 | $-2.02 | · | · | $-2.97 | |
| EPS (Diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | · | · | · | · | $-2.97 | |
| Shares (Basic) | 79,534,290 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| Shares (Diluted) | 88,311,494 | 76,845,055 | 74,838,292 | 71,728,634 | 70,466,393 | 66,027,908 | 58,863,185 | · | · | · | · | 31,565,310 | |
| EBITDA | $906M | $-227M | $-203M | · | $-310M | $-388M | $-209M | $-90M | $-47M | $-132M | $-167M | $-99M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $985M | $780M | $594M | $280M | $190M | $209M | $288M | $169M | $112M | $58M | $58M | $50M | |
| Short-term Investments | $961M | $360M | $283M | $131M | $584M | $895M | $399M | $58M | $79M | $173M | $281M | $265M | |
| Receivables | $182M | $159M | $161M | $156M | $110M | $70M | $56M | $68M | $40M | $25M | $11M | $4M | |
| Inventory | $80M | $23M | $31M | $22M | $16M | $19M | $19M | $16M | $11M | $0 | · | · | |
| Prepaid Expense | $67M | $44M | $150M | $106M | $55M | $39M | $18M | $9M | $7M | $5M | $6M | $4M | |
| Current Assets | $2.27B | $1.37B | $1.22B | $694M | $954M | $1.23B | $779M | $321M | $249M | $261M | $356M | $324M | |
| PP&E (Net) | $55M | $61M | $87M | $73M | $53M | $34M | $22M | $13M | $8M | $7M | $9M | $9M | |
| PP&E (Gross) | $102M | $94M | $138M | $110M | $80M | $52M | $33M | $20M | $41M | $38M | $37M | $34M | |
| Accum. Depreciation | $47M | $33M | $51M | $37M | $27M | $18M | $12M | $7M | $33M | $31M | $28M | $25M | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $0 | · | · | · | |
| Intangibles | $389M | $119M | $379M | $706M | $725M | $715M | $710M | $701M | $133M | $0 | · | · | |
| Total Assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Accounts Payable | $45M | $17M | $6M | $27M | $23M | $19M | $10M | $6M | $15M | $6M | $6M | $4M | |
| Current Liabilities | $968M | $581M | $603M | $406M | $509M | $277M | $236M | $167M | $82M | $50M | $45M | $32M | |
| Capital Leases | $94M | $75M | $98M | $101M | $74M | $79M | $9M | · | · | · | · | · | |
| Deferred Tax | · | · | $56M | $103M | $137M | $137M | $131M | $122M | $0 | · | · | · | |
| Other Non-current Liabilities | $14M | $21M | $141.0K | $3M | · | $1M | $141.0K | $58.0K | $243.0K | $335.0K | $2M | $2M | |
| Total Liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768M | $235M | $150M | $139M | $35M | |
| Long-term Debt | · | · | · | · | $431M | · | $314M | $153M | $145M | · | · | · | |
| Total Debt | $287M | $285M | $284M | · | $431M | $309M | $314M | $153M | $145M | $98M | $95M | · | |
| Common Stock | $80.0K | $77.0K | $75.0K | $72.0K | $71.0K | $70.0K | $62.0K | $51.0K | $42.0K | $34.0K | $34.0K | $33.0K | |
| Paid-in Capital | $2.75B | $2.57B | $2.47B | $2.31B | $2.12B | $2.17B | $1.80B | $1.29B | $967M | $856M | $820M | $722M | |
| Retained Earnings | $-2.96B | $-3.65B | $-3.28B | $-2.66B | $-2.10B | $-1.63B | $-1.19B | $-939M | $-814M | $-735M | $-593M | $-423M | |
| AOCI | $11M | $-26M | $-1M | $5M | $-24M | $-61M | $-11M | $1M | $4M | $-1M | $-1M | $-737.0K | |
| Stockholders' Equity | $-205M | $-1.10B | $-819M | $-347M | $1M | $482M | $594M | $351M | $156M | $120M | $226M | $298M | |
| Liabilities + Equity | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $392M | $269M | $365M | $333M | |
| Shares Outstanding | 81,474,366 | 77,704,188 | 75,708,889 | 73,104,692 | 70,828,226 | 69,718,096 | 61,935,870 | 50,606,147 | 41,612,395 | 34,169,410 | 33,916,559 | 32,898,392 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $39M | $76M | $237M | $129M | $64M | $43M | $32M | $26M | $18M | $3M | $3M | · | |
| Stock-based Comp | $75M | $75M | $102M | $110M | $104M | $70M | $42M | $33M | $31M | $35M | $34M | $19M | |
| Deferred Tax | $-3.0K | $-56M | $-47M | $-34M | $377.0K | $6M | $9M | $0 | $199.0K | $-199.0K | $0 | $0 | |
| Amort. of Intangibles | $25M | $61M | $223M | $117M | $55M | $37M | $28M | $23M | $15M | $0 | $0 | · | |
| Restructuring | · | · | · | · | · | · | · | · | $0 | · | · | · | |
| Other Non-cash | $-85M | $161M | $177M | · | $105M | $124M | $70M | $41M | $20M | · | · | · | |
| Operating Cash Flow | $711M | $-108M | $-158M | $-357M | $-251M | $-194M | $-99M | $-28M | $-10M | $-104M | $-124M | $-57M | |
| CapEx | $9M | $7M | $28M | $32M | $28M | $18M | $14M | $7M | $3M | $2M | $3M | $5M | |
| Investing Cash Flow | $-862M | $44M | $-177M | $290M | $219M | $-562M | $-387M | $-43M | $13M | $104M | $-21M | $-145M | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | $-49.0K | |
| Stock Issued | · | · | · | · | · | $28M | $324M | $118M | $0 | $0 | $0 | $236M | |
| Net Stock Activity | · | · | · | · | · | $28M | $324M | $118M | · | $0 | · | $236M | |
| Financing Cash Flow | $331M | $256M | $646M | $168M | $21M | $669M | $613M | $132M | $44M | $968.0K | $154M | $237M | |
| Net Change in Cash | $203M | $185M | $314M | $99M | $-19M | $-79M | $126M | $58M | $53M | $299.0K | $8M | $34M | |
| Taxes Paid | $37M | $18M | $14M | $5M | $8M | $26M | $2M | $2M | $1M | $943.0K | $111.0K | $0 | |
| Free Cash Flow | $702M | $-114M | $-187M | · | $-280M | $-212M | $-112M | $-35M | $-13M | $-105M | $-127M | $-62M |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 50.1% | -37.5% | -46.9% | · | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% | -454.6% | -393.8% | |
| Net Margin | 39.4% | -45.0% | -66.8% | · | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% | -463.6% | -371.4% | |
| Pretax Margin | 40.2% | -45.0% | -74.2% | · | -96.2% | -105.8% | -78.2% | -48.4% | -40.0% | -171.1% | -462.3% | -390.0% | |
| EBITDA Margin | 52.3% | -28.1% | -21.6% | · | -57.6% | -102.0% | -68.1% | -33.8% | -24.0% | -159.7% | -454.6% | -393.8% | |
| ROA | 29.7% | -20.2% | -34.8% | · | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.8% | -48.6% | -38.6% | |
| ROE | -331.5% | 33.8% | 84.1% | · | -985.1% | -88.3% | -40.0% | -34.8% | -57.2% | -82.2% | -65.0% | -43.1% | |
| ROIC | 1044.7% | 37.2% | 74.0% | · | -87.4% | -59.4% | -27.8% | -23.0% | -21.7% | -60.9% | -52.3% | -31.7% |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 2.4 | 2.0 | · | 1.9 | 4.4 | 3.3 | 1.9 | 3.0 | 5.3 | 7.8 | 10.0 | |
| Quick Ratio | 2.2 | 2.2 | 1.7 | · | 1.7 | 4.2 | 3.1 | 1.8 | 2.8 | 5.2 | 7.7 | 9.8 | |
| Debt / Equity | -1.4 | -0.3 | -0.3 | · | 300.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · | |
| LT Debt / Equity | · | -0.3 | -0.3 | · | 196.0 | 0.6 | 0.5 | 0.4 | 0.9 | 0.8 | 0.4 | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.4 | 0.5 | · | 0.3 | 0.2 | 0.2 | 0.4 | 0.6 | 0.3 | 0.1 | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | 0.7 | · | 0.9 | · | · | · | |
| Receivables Turnover | 10.2 | 5.1 | 5.9 | · | 6.0 | 6.1 | 5.0 | 4.9 | 6.0 | 4.6 | 4.7 | 9.3 |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.52 | $-14.13 | $-10.81 | · | $0.02 | $6.91 | $9.60 | $6.93 | $3.76 | $3.50 | $6.66 | $9.07 | |
| Revenue / Share | $19.60 | $10.50 | $12.53 | · | $7.64 | · | · | · | · | · | · | $0.80 | |
| Cash Flow / Share | $8.05 | $-1.40 | $-2.12 | · | $-3.57 | · | · | · | · | · | · | $-1.81 | |
| Cash / Share | $12.09 | $10.03 | $7.85 | · | $2.68 | $3.00 | $4.65 | $3.35 | $2.69 | $1.71 | $1.71 | $1.51 | |
| EPS (TTM) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 | $-6.64 | $-4.27 | $-3.21 | $-3.21 | $-3.21 | $-3.21 | $-2.97 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 114.5% | -14.0% | 34.2% | 29.8% | 41.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 35.3% | 14.4% | 35.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 35.4% | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.73B | $807M | $938M | $699M | $539M | $381M | $307M | $265M | $194M | $83M | $37M | $25M | |
| Net Income TTM | $683M | $-363M | $-627M | $-559M | $-524M | $-438M | $-252M | $-128M | $-79M | $-142M | $-170M | $-94M | |
| Market Cap | $6.19B | $3.51B | $2.09B | · | $2.82B | $4.25B | $2.97B | $1.74B | $694M | $373M | $1.10B | $1.70B | |
| Enterprise Value | $4.53B | $2.65B | $1.49B | · | $2.48B | $3.46B | $2.60B | $1.66B | $648M | $239M | $855M | · | |
| P/E | 9.8 | -9.5 | -3.3 | -4.9 | -5.4 | -9.2 | -11.2 | -10.7 | -5.2 | -3.4 | -10.1 | -17.4 | |
| P/S | 3.6 | 4.3 | 2.2 | · | 5.2 | 11.2 | 9.7 | 6.6 | 3.6 | 4.5 | 29.9 | 67.5 | |
| P/B | -30.1 | -3.2 | -2.5 | · | 1961.8 | 8.8 | 5.0 | 5.0 | 4.4 | 3.1 | 4.9 | 5.7 | |
| P / Cash Flow | 8.7 | -32.6 | -13.2 | · | -11.2 | -21.9 | -30.2 | -62.8 | -69.0 | -3.6 | -8.8 | -29.7 | |
| P / FCF | 8.8 | -30.7 | -11.2 | · | -10.1 | -20.1 | -26.5 | -50.0 | -52.7 | -3.5 | -8.6 | -27.5 | |
| EV / EBITDA | 5.0 | -11.7 | -7.4 | · | -8.0 | -8.9 | -12.5 | -18.6 | -13.9 | -1.8 | -5.1 | · | |
| EV / FCF | 6.5 | -23.2 | -8.0 | · | -8.9 | -16.3 | -23.2 | -47.9 | -49.2 | -2.3 | -6.7 | · | |
| EV / Revenue | 2.6 | 3.3 | 1.6 | · | 4.6 | 9.1 | 8.5 | 6.3 | 3.3 | 2.9 | 23.2 | · | |
| Earnings Yield | 10.2% | -10.5% | -30.4% | -20.4% | -18.6% | -10.9% | -8.9% | -9.3% | -19.2% | -29.4% | -9.9% | -5.7% |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $361M | $273M | $165M | $211M | $179M | $1.18B | $213M | $197M | $187M | $210M | $307M | $197M | $214M | $220M | $167M | $217M | |
| R&D Expense | $99M | $101M | $133M | $100M | $113M | $109M | $125M | $161M | $132M | $116M | $121M | $164M | $186M | $195M | $189M | $165M | |
| SG&A Expense | $81M | $86M | $97M | $84M | $85M | $81M | $85M | $73M | $70M | $73M | $76M | $81M | $88M | $87M | $93M | $80M | |
| Operating Expenses | $212M | $228M | $236M | $208M | $214M | $206M | $376M | $251M | $227M | $256M | $301M | $315M | $423M | $338M | $368M | $285M | |
| Operating Income | $149M | $45M | $-71M | $3M | $-35M | $970M | $-162M | $-55M | $-40M | $-45M | $6M | $-118M | $-210M | $-118M | $-200M | $-68M | |
| Other Non-op | $-3M | $2M | $-13M | $7M | $-6M | $-6M | $9M | $-2M | $-2M | $2M | $19M | $-20M | $1M | $10M | $35M | $-38M | |
| Pretax Income | $98M | $-2M | $-139M | $-23M | $-71M | $930M | $-95M | $-98M | $-86M | $-85M | $-157M | $-167M | $-237M | $-135M | $-190M | $-127M | |
| Income Tax | $14M | $347.0K | $-4M | $-39M | $-6M | $63M | $-29M | $9M | $13M | $7M | $-1M | $-34M | $-39M | $4M | $-19M | $-18M | |
| Net Income | $83M | $-3M | $-135M | $16M | $-65M | $867M | $-66M | $-107M | $-99M | $-92M | $-156M | $-133M | $-199M | $-139M | $-171M | $-109M | |
| EPS (Basic) | $1.01 | $-0.03 | $-1.88 | $0.20 | $-0.83 | $11.09 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| EPS (Diluted) | $0.92 | $-0.03 | $-1.63 | $0.20 | $-0.83 | $10.04 | $-0.85 | $-1.39 | $-1.29 | $-1.20 | $-2.07 | $-1.76 | $-2.66 | $-1.88 | $-2.35 | $-1.53 | |
| Shares (Basic) | 83,006,808 | 82,521,023 | · | 78,471,119 | 78,151,240 | 78,115,836 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| Shares (Diluted) | 92,020,009 | 82,521,023 | · | 87,115,369 | 78,151,240 | 86,385,922 | · | 76,925,523 | 76,725,070 | 76,496,127 | · | 75,377,997 | 74,730,433 | 73,729,284 | · | 71,654,671 | |
| EBITDA | $149M | $60M | · | $3M | $-35M | $977M | · | $-55M | $-40M | $10M | · | $-118M | $-210M | $-75M | · | $-68M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.05B | $834M | $985M | $673M | $1.02B | $1.48B | $780M | $526M | $655M | $548M | · | $165M | $208M | $167M | · | $104M | |
| Short-term Investments | $1.18B | $1.06B | $961M | $1.02B | $972M | $547M | $360M | $487M | $439M | $336M | · | $130M | $130M | $119M | · | $184M | |
| Receivables | $239M | $220M | $182M | $203M | $196M | $210M | $159M | $200M | $187M | $198M | · | $166M | $178M | $202M | · | $124M | |
| Inventory | $91M | $76M | $80M | $53M | $34M | $22M | $23M | $36M | $32M | $30M | · | $36M | $32M | $27M | · | $15M | |
| Prepaid Expense | $58M | $66M | $67M | $64M | $54M | $57M | $44M | $33M | $46M | $56M | · | $44M | $42M | $99M | · | $90M | |
| Current Assets | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B | $1.28B | $1.36B | $1.17B | · | $540M | $590M | $613M | · | $517M | |
| PP&E (Net) | $51M | $53M | $55M | $57M | $57M | $59M | $61M | $63M | $66M | $93M | · | $85M | $82M | $79M | · | $67M | |
| PP&E (Gross) | · | · | $102M | · | · | · | $94M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $47M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | $82M | · | $82M | $82M | $82M | · | $82M | |
| Intangibles | $403M | $381M | $389M | $396M | $144M | $118M | $119M | $330M | $330M | $330M | · | $423M | $452M | $686M | · | $750M | |
| Total Assets | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Accounts Payable | $40M | $25M | $45M | $37M | $27M | $15M | $17M | $13M | $24M | $27M | · | $19M | $26M | $26M | · | $21M | |
| Current Liabilities | $771M | $924M | $968M | $866M | $628M | $595M | $581M | $611M | $610M | $575M | · | $492M | $476M | $442M | · | $420M | |
| Capital Leases | $88M | $90M | $94M | $95M | $71M | $74M | $75M | $83M | $79M | $105M | · | $100M | $100M | $100M | · | $102M | |
| Deferred Tax | · | · | · | · | · | · | · | $56M | $56M | $56M | · | $52M | $52M | $103M | · | $137M | |
| Other Non-current Liabilities | $15M | $14M | $14M | $3M | $8M | $22M | $21M | $77.0K | $141.0K | $141.0K | · | $141.0K | $141.0K | $141.0K | · | $5M | |
| Total Liabilities | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B | $2.90B | $2.90B | $2.68B | · | $1.93B | $1.92B | $2.07B | · | $1.80B | |
| Long-term Debt | $591M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $591M | $287M | · | $286M | $286M | $286M | · | $285M | $285M | $285M | · | $573M | $573M | $572M | · | $283M | |
| Common Stock | $82.0K | $81.0K | $80.0K | $79.0K | $78.0K | $78.0K | $77.0K | $76.0K | $76.0K | $76.0K | · | $75.0K | $75.0K | $73.0K | · | $71.0K | |
| Paid-in Capital | $2.71B | $2.78B | $2.75B | $2.67B | $2.63B | $2.61B | $2.57B | $2.53B | $2.51B | $2.49B | · | $2.45B | $2.42B | $2.34B | · | $2.22B | |
| Retained Earnings | $-2.88B | $-2.97B | $-2.96B | $-2.83B | $-2.85B | $-2.78B | $-3.65B | $-3.58B | $-3.47B | $-3.38B | · | $-3.13B | $-2.99B | $-2.80B | · | $-2.49B | |
| AOCI | $6M | $8M | $11M | $6M | $7M | $-14M | $-26M | $-4M | $-16M | $-6M | · | $10M | $-1M | $-2M | · | $36M | |
| Stockholders' Equity | $-165M | $-180M | $-205M | $-156M | $-207M | $-186M | $-1.10B | $-1.05B | $-980M | $-894M | $-819M | $-671M | $-579M | $-458M | $-347M | $-227M | |
| Liabilities + Equity | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B | $1.84B | $1.92B | $1.79B | · | $1.26B | $1.34B | $1.61B | · | $1.58B | |
| Shares Outstanding | 83,327,286 | 82,882,024 | 81,474,366 | 79,931,766 | 79,378,145 | 79,225,276 | 77,704,188 | 76,952,124 | 76,900,123 | 76,653,960 | · | 75,459,022 | 75,318,233 | 74,012,034 | · | 71,854,892 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $16M | $15M | $13M | $11M | $8M | $7M | $7M | $6M | $7M | $55M | $81M | $62M | $51M | $43M | $39M | $34M | |
| Stock-based Comp | $23M | $23M | $19M | $19M | $19M | $18M | $17M | $20M | $19M | $18M | $17M | $27M | $29M | $29M | $27M | $29M | |
| Deferred Tax | · | $-10.0K | $1.0K | · | · | $2.0K | $-56M | $-3.0K | $2.0K | $-1.0K | $4M | $-2.0K | $-51M | $-4.0K | · | · | |
| Amort. of Intangibles | $12M | $12M | $9M | $8M | $4M | $4M | $3M | $3M | $3M | $52M | $77M | $59M | $47M | $39M | $36M | $31M | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | $23M | $8M | · | · | · | |
| Other Non-cash | · | $-95M | · | · | · | $-22M | · | · | · | $89M | · | · | · | $38M | · | · | |
| Operating Cash Flow | $129M | $-59M | $-34M | $-66M | $-58M | $870M | $-30M | $-77M | $-71M | $71M | $-100M | $-15M | $-14M | $-29M | $-166M | $-38M | |
| CapEx | $2M | $1M | $2M | $3M | $1M | $2M | $4M | $522.0K | $-7M | $10M | $6M | $6M | $6M | $10M | $9M | $5M | |
| Investing Cash Flow | $-123M | $-94M | $34M | $-290M | $-422M | $-184M | $268M | $-43M | $-66M | $-115M | $-94M | $-30M | $-24M | $-29M | $32M | $136M | |
| Financing Cash Flow | $212M | $6M | $303M | $15M | $4M | $9M | $26M | $-18M | $246M | $540.0K | $620M | $3M | $18M | $4M | $303M | $-140M | |
| Net Change in Cash | $216M | $-148M | $312M | $-347M | $-463M | $701M | $256M | $-129M | $104M | $-46M | $429M | $-43M | $-9M | $-62M | $175M | $-54M | |
| Taxes Paid | · | · | $-3M | $936.0K | $36M | $3M | $5M | $7M | $4M | $2M | $524.0K | $4M | $7M | $2M | $893.0K | $1M | |
| Free Cash Flow | · | $-60M | · | · | · | $868M | · | · | · | $61M | · | · | · | $-40M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 41.3% | 16.5% | · | 1.4% | -19.5% | 82.5% | · | -27.7% | -21.5% | -21.6% | · | -60.1% | -98.0% | -53.4% | · | -31.4% | |
| Net Margin | 23.2% | -1.0% | · | 7.5% | -36.2% | 73.7% | · | -54.2% | -53.1% | -43.6% | · | -67.6% | -93.0% | -63.0% | · | -50.3% | |
| Pretax Margin | 27.1% | -0.90% | · | -10.9% | -39.7% | 79.1% | · | -49.8% | -45.9% | -40.3% | · | -84.8% | -111.1% | -61.3% | · | -58.6% | |
| EBITDA Margin | 41.3% | 22.1% | · | 1.4% | -19.5% | 83.1% | · | -27.7% | -21.5% | 4.7% | · | -60.1% | -98.0% | -33.9% | · | -31.4% | |
| ROA | 2.8% | -0.10% | · | 0.71% | -2.9% | 39.0% | · | -6.9% | -6.1% | -5.4% | · | -9.4% | -12.7% | -8.2% | · | -6.1% | |
| ROE | -44.9% | 1.5% | · | -2.6% | 10.9% | -160.5% | · | 12.4% | 12.7% | 13.6% | · | 29.6% | 52.2% | 50.7% | · | 179.2% | |
| ROIC | 30.0% | 48.2% | · | -1.6% | -40.2% | 904.6% | · | 7.7% | 6.7% | 8.1% | · | 96.6% | 2648.9% | -105.7% | · | -104.9% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 2.4 | · | 2.3 | 3.6 | 3.9 | · | 2.1 | 2.2 | 2.0 | · | 1.1 | 1.2 | 1.4 | · | 1.2 | |
| Quick Ratio | 3.2 | 2.3 | · | 2.2 | 3.5 | 3.8 | · | 2.0 | 2.1 | 1.9 | · | 0.9 | 1.1 | 1.1 | · | 1.0 | |
| Debt / Equity | -3.6 | -1.6 | · | -1.8 | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 | |
| LT Debt / Equity | -3.2 | · | · | · | -1.4 | -1.5 | · | -0.3 | -0.3 | -0.3 | · | -0.9 | -1.0 | -1.3 | · | -1.2 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.5 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.7 | 1.3 | · | 1.0 | 0.9 | 5.8 | · | 1.1 | 1.0 | 1.1 | · | 1.4 | 1.4 | 1.3 | · | 2.0 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.98 | $-2.18 | · | $-1.95 | $-2.60 | $-2.34 | · | $-13.70 | $-12.75 | $-11.66 | · | $-8.89 | $-7.69 | $-6.18 | · | $-3.16 | |
| Revenue / Share | $3.92 | $3.30 | · | $2.42 | $2.29 | $13.61 | · | $2.56 | $2.43 | $2.75 | · | $2.61 | $2.86 | $2.99 | · | $3.03 | |
| Cash Flow / Share | · | $-0.72 | · | · | · | $10.07 | · | · | · | $0.93 | · | · | · | $-0.40 | · | · | |
| Cash / Share | $12.60 | $10.06 | · | $8.41 | $12.82 | $18.68 | · | $6.84 | $8.51 | $7.15 | · | $2.19 | $2.77 | $2.26 | · | $1.45 | |
| EPS (TTM) | $-0.54 | $-2.29 | · | $8.56 | $6.97 | $6.51 | · | $-5.95 | $-6.32 | $-7.69 | · | $-8.65 | $-8.42 | $-7.89 | · | $-7.47 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.01B | $827M | · | $1.78B | $1.76B | $1.77B | · | $901M | $900M | $928M | · | $798M | $819M | $770M | · | $697M | |
| Net Income TTM | $-38M | $-187M | · | $752M | $629M | $595M | · | $-453M | $-480M | $-579M | · | $-642M | $-618M | $-571M | · | $-531M | |
| Market Cap | $6.80B | $5.65B | · | $4.91B | $3.88B | $4.04B | · | $2.85B | $2.35B | $2.23B | · | $1.69B | $3.06B | $3.59B | · | $3.61B | |
| Enterprise Value | $5.16B | $4.04B | · | $3.50B | $2.17B | $2.30B | · | $2.13B | $1.54B | $1.63B | · | $1.97B | $3.30B | $3.87B | · | $3.60B | |
| P/E | -151.1 | -29.8 | · | 7.2 | 7.0 | 7.8 | · | -6.2 | -4.8 | -3.8 | · | -2.6 | -4.8 | -6.1 | · | -6.7 | |
| P/S | 6.7 | 6.8 | · | 2.8 | 2.2 | 2.3 | · | 3.2 | 2.6 | 2.4 | · | 2.1 | 3.7 | 4.7 | · | 5.2 | |
| P/B | -41.1 | -31.3 | · | -31.5 | -18.8 | -21.7 | · | -2.7 | -2.4 | -2.5 | · | -2.5 | -5.3 | -7.8 | · | -15.9 | |
| P / Cash Flow | · | -95.6 | · | · | · | 4.6 | · | · | · | 31.5 | · | · | · | -121.6 | · | · | |
| EV / Revenue | 5.1 | 4.9 | · | 2.0 | 1.2 | 1.3 | · | 2.4 | 1.7 | 1.8 | · | 2.5 | 4.0 | 5.0 | · | 5.2 | |
| Earnings Yield | -0.66% | -3.4% | · | 14.0% | 14.3% | 12.8% | · | -16.0% | -20.7% | -26.4% | · | -38.6% | -20.7% | -16.3% | · | -14.9% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $1.73B | $807M | $938M | $699M | $539M |
| Margen Operativo % | 50.1% | -37.5% | -46.9% | · | -69.5% |
| Beneficio neto | $683M | $-363M | $-627M | $-559M | $-524M |
| EPS Diluido | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -1.4 | -0.3 | -0.3 | · | 300.0 |
| Ratio corriente | 2.3 | 2.4 | 2.0 | · | 1.9 |
| Ratio Rápido | 2.2 | 2.2 | 1.7 | · | 1.7 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | $702M | $-114M | $-187M | · | $-280M |
Propietarios institucionales (13F) 403 declarantes · $8.6B total · A fecha de 30 de septiembre de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Tenedores
403
Valor en tenencia
$8.6B
Nuevas posiciones
76
Posiciones cerradas
43
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 76 (+7 vs trimestre anterior) | 43 (-7 vs trimestre anterior) | 140 (+3 vs trimestre anterior) | 114 (+10 vs trimestre anterior) | -1.4M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $1 139 088 671 | 13 964 554 | 13,21% | Acciones |
| VANGUARD GROUP INC | $668 691 300 | 8 803 203 | 7,75% | Acciones |
| RTW INVESTMENTS, LP | $631 875 072 | 7 746 415 | 7,33% | Acciones |
| JANUS HENDERSON GROUP PLC | $489 997 100 | 7 193 433 | 5,68% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $401 986 014 | 4 928 111 | 4,66% | Acciones |
| STATE STREET CORP | $375 136 515 | 4 598 952 | 4,35% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $336 743 228 | 4 128 273 | 3,90% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $305 000 589 | 3 739 127 | 3,54% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $180 089 116 | 2 207 376 | 2,09% | Acciones |
| TORONTO DOMINION BANK | $176 668 031 | 2 165 846 | 2,05% | Acciones |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $159 563 645 | 1 956 156 | 1,85% | Acciones |
| Hood River Capital Management LLC | $141 818 662 | 1 738 613 | 1,64% | Acciones |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | $140 519 660 | 1 722 688 | 1,63% | Acciones |
| D. E. Shaw & Co., Inc. | $126 345 323 | 1 548 919 | 1,47% | Acciones |
| TANG CAPITAL MANAGEMENT LLC | $122 355 000 | 1 500 000 | 1,42% | Acciones |
| BANK OF AMERICA CORP /DE/ | $118 462 234 | 1 452 277 | 1,37% | Acciones |
| Driehaus Capital Management LLC | $117 469 528 | 1 440 107 | 1,36% | Acciones |
| FMR LLC | $114 056 206 | 1 398 261 | 1,32% | Acciones |
| Jefferies Financial Group Inc. | $110 693 916 | 1 357 042 | 1,28% | Acciones |
| FULLER & THALER ASSET MANAGEMENT, INC. | $94 361 749 | 1 156 819 | 1,09% | Acciones |
| Pictet Asset Management Holding SA | $93 629 635 | 1 147 844 | 1,09% | Acciones |
| MORGAN STANLEY | $90 026 886 | 1 103 675 | 1,04% | Acciones |
| ARMISTICE CAPITAL, LLC | $87 393 690 | 1 071 395 | 1,01% | Acciones |
| Blue Sparrow, LLC /DE | $85 705 599 | 1 050 700 | 0,99% | Acciones |
| FRANKLIN RESOURCES INC | $83 799 082 | 1 027 327 | 0,97% | Acciones |
| Invesco Ltd. | $76 804 761 | 941 581 | 0,89% | Acciones |
| Palo Alto Investors LP | $74 950 268 | 918 846 | 0,87% | Acciones |
| NORTHERN TRUST CORP | $71 783 966 | 880 029 | 0,83% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $64 449 436 | 790 112 | 0,75% | Acciones |
| CITADEL ADVISORS LLC | $60 999 840 | 747 822 | 0,71% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $59 015 895 | 723 500 | 0,68% | Acciones |
| Boston Partners | $58 606 553 | 718 574 | 0,68% | Acciones |
| JUPITER ASSET MANAGEMENT LTD | $57 706 697 | 707 450 | 0,67% | Acciones |
| MARSHALL WACE, LLP | $57 489 476 | 704 787 | 0,67% | Acciones |
| JPMORGAN CHASE & CO | $56 073 502 | 684 042 | 0,65% | Acciones |
| ARMISTICE CAPITAL, LLC | $53 836 200 | 660 000 | 0,62% | Opción de compra |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $53 377 940 | 654 382 | 0,62% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $52 017 434 | 637 704 | 0,60% | Acciones |
| GOLDMAN SACHS GROUP INC | $50 430 408 | 618 247 | 0,58% | Acciones |
| LOOMIS SAYLES & CO L P | $48 156 807 | 590 374 | 0,56% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $47 953 943 | 587 887 | 0,56% | Acciones |
| Nuveen, LLC | $47 622 931 | 583 829 | 0,55% | Acciones |
| Bank of New York Mellon Corp | $45 145 865 | 553 462 | 0,52% | Acciones |
| PRINCIPAL FINANCIAL GROUP INC | $44 181 166 | 541 635 | 0,51% | Acciones |
| VOYA INVESTMENT MANAGEMENT LLC | $43 992 251 | 539 319 | 0,51% | Acciones |
| Ensign Peak Advisors, Inc | $41 442 128 | 508 056 | 0,48% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $40 866 277 | 500 995 | 0,47% | Acciones |
| FEDERATED HERMES, INC. | $39 432 896 | 483 424 | 0,46% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $36 050 432 | 441 957 | 0,42% | Acciones |
| Parkman Healthcare Partners LLC | $35 539 315 | 435 691 | 0,41% | Acciones |
Activistas y propietarios del %+ 5 3 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Brookside Capital Partners Fund, L.P., Brookside Capital Trading Fund, L.P. ×5 presentaciones | 30 de enero de 2015 | · | Presentación inicial | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. (“HBM”) ×2 presentaciones | 12 de noviembre de 2014 | · | Presentación inicial | · | SEC |
| HBM Healthcare Investments (Cayman) Ltd. | 5 de julio de 2013 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 37 insiders · 15 directivos · 20 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Matthew B. Klein | CHIEF EXECUTIVE OFFICER | 4 de agosto de 2026 S | 383 868 | 0 | 13 | $-4 219 888 |
| Stuart Walter Peltz | CHIEF EXECUTIVE OFFICER | 31 de enero de 2023 S | 54 903 | 0 | 0 | $0 |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 14 de julio de 2026 S | 83 986 | 0 | 3 | $-652 864 |
| Emily Luisa Hill | CHIEF FINANCIAL OFFICER | 27 de marzo de 2023 S | 38 925 | 0 | 0 | $0 |
| Shane William Charles Kovacs | Chief Financial Officer | 9 de mayo de 2017 M | 37 850 | 0 | 0 | $0 |
| Claudia De Oliveira Ribeiro Hirawat | President | 15 de enero de 2015 M | 39 247 | 0 | 0 | $0 |
| Marcio Souza | Chief Operating Officer | 10 de febrero de 2020 M | 6 744 | 0 | 0 | $0 |
| Mark Elliott Boulding | EXEC. VP AND CLO | 17 de agosto de 2026 M | 105 272 | 0 | 63 | $-5 955 553 |
| Neil Gregory Almstead | CHIEF TECHNICAL OPS OFFICER | 9 de julio de 2026 M | 60 299 | 0 | 62 | $-25 989 291 |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 17 de junio de 2026 M | 70 199 | 0 | 5 | $-1 941 426 |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 10 de junio de 2026 S | 73 411 | 0 | 28 | $-7 477 160 |
| Lee Scott Golden | EVP & CHIEF MEDICAL OFFICER | 2 de abril de 2026 S | 79 115 | 0 | 6 | $-1 081 515 |
| Mark Rothera | Chief Commercial Officer | 24 de mayo de 2017 M | 33 739 | 0 | 0 | $0 |
| Tuyen Ong | Chief Medical Officer | 3 de enero de 2017 A | 6 000 | 0 | 0 | $0 |
| Robert J. Spiegel | Chief Medical Officer | 4 de enero de 2016 A | 3 239 | 0 | 0 | $0 |
| Glenn Steele JR MD PHD | Consejero | 30 de septiembre de 2026 M | 22 500 | 0 | 2 | $-1 698 120 |
| Michael Schmertzler | Consejero | 17 de septiembre de 2026 S | 1 296 594 | 0 | 16 | $-6 313 453 |
| Hege Elisabeth Sollie-Zetlmayer | Consejero | 28 de julio de 2026 A | 52 526 | 0 | 0 | $0 |
| Mary L. Smith | Consejero | 9 de julio de 2026 M | 21 813 | 0 | 2 | $-1 425 060 |
| Jessica Caroline Chutter | Consejero | 24 de marzo de 2026 A | 7 333 | 0 | 0 | $0 |
| Stephanie Okey | Consejero | 10 de marzo de 2026 M | 8 000 | 0 | 3 | $-1 463 076 |
| Emma Reeve | Consejero | 5 de enero de 2026 M | 10 666 | 0 | 15 | $-4 229 530 |
| Alethia Young | Consejero | 2 de enero de 2026 A | 21 067 | 0 | 0 | $0 |
| Allan Steven Jacobson | Consejero | 2 de enero de 2026 A | 21 451 | 0 | 11 | $-2 912 018 |
| Jerome B Zeldis | Consejero | 2 de enero de 2026 A | 22 500 | 0 | 0 | $0 |
| William F. Bell Jr. | Consejero | 15 de febrero de 2024 A | 10 333 | 0 | 0 | $0 |
| Dawn Svoronos | Consejero | 9 de junio de 2022 S | 29 017 | 0 | 0 | $0 |
| Cameron Geoffrey Mcdonough | Consejero | 3 de enero de 2017 A | · | 0 | 0 | $0 |
| Adam Koppel | Consejero | 3 de enero de 2017 A | 2 333 333 | 0 | 0 | $0 |
| Ronald C Renaud JR | Consejero | 3 de enero de 2017 A | · | 0 | 0 | $0 |
| Richard Aldrich | Consejero | 8 de junio de 2015 M | 0 | 0 | 0 | $0 |
| Michael L Kranda | Consejero | 16 de marzo de 2015 S | 2 242 | 0 | 0 | $0 |
| Axel Bolte | Consejero | 25 de junio de 2013 P | 20 000 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | Propietario del 10% | 17 de diciembre de 2013 S | 2 441 504 | 0 | 0 | $0 |
| David P Southwell | · | 2 de enero de 2026 A | 20 850 | 0 | 0 | $0 |
| Complete Pharma Holdings II, LLC | · | 28 de abril de 2017 J | 0 | 0 | 0 | $0 |
| CREDIT SUISSE/ | · | 25 de junio de 2013 C | 2 256 882 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 68 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| IBRN · iShares Trust | 3,74% | 4 145 SH | 11 de septiembre de 2026 | Diario |
| PSCH · Invesco Exchange-Traded Fund Trust … | 2,93% | 79 357 SH | 2 de octubre de 2026 | Diario |
| PBE · Invesco Exchange-Traded Fund Trust | 2,47% | 159 717 SH | 2 de octubre de 2026 | Diario |
| MEDI · Harbor ETF Trust | 1,31% | 7 913 NS | 31 de julio de 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,25% | 18 062 NS | 31 de julio de 2026 | N-PORT |
| RZG · Invesco Exchange-Traded Fund Trust | 1,23% | 22 852 SH | 2 de octubre de 2026 | Diario |
| JSML · Janus Detroit Street Trust | 1,03% | 54 825 NS | 31 de julio de 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0,94% | 145 033 NS | 31 de julio de 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,74% | 98 733 SH | 19 de agosto de 2026 | Diario |
| VAMO · Cambria ETF Trust | 0,72% | 11 494 NS | 31 de julio de 2026 | N-PORT |
| VMAX · Lattice Strategies Trust | 0,71% | 5 120 NS | 31 de julio de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,63% | 46 006 NS | 31 de julio de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,49% | 658 NS | 31 de julio de 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,42% | 3 031 NS | 31 de julio de 2026 | N-PORT |
| IBB · iShares Trust | 0,40% | 613 266 SH | 11 de septiembre de 2026 | Diario |
| BRNY · EA Series Trust | 0,39% | 33 006 NS | 31 de julio de 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,37% | 290 018 SH | 19 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,36% | 5 891 SH | 2 de octubre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,34% | 75 795 SH | 19 de agosto de 2026 | Diario |
| ESSC · Strategy Shares | 0,34% | 1 785 NS | 31 de julio de 2026 | N-PORT |
| IWO · iShares Trust | 0,31% | 664 357 SH | 11 de septiembre de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,27% | 22 505 NS | 31 de julio de 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,25% | 25 676 NS | 31 de julio de 2026 | N-PORT |
| BKSE · BNY Mellon ETF Trust | 0,24% | 3 125 NS | 31 de julio de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,20% | 477 030 SH | 19 de agosto de 2026 | Diario |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,19% | 19 797 NS | 31 de julio de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,19% | 3 667 NS | 31 de julio de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,19% | 1 099 640 SH | 19 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,18% | 2 118 779 SH | 11 de septiembre de 2026 | Diario |
| RSSL · Global X Funds | 0,18% | 39 691 NS | 31 de julio de 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0,18% | 629 NS | 31 de julio de 2026 | N-PORT |
| ISCG · iShares Trust | 0,16% | 23 005 SH | 11 de septiembre de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,16% | 65 468 SH | 2 de octubre de 2026 | Diario |
| LRGF · iShares Trust | 0,16% | 84 774 SH | 11 de septiembre de 2026 | Diario |
| VFMO · VANGUARD WELLINGTON FUND | 0,14% | 35 428 SH | 19 de agosto de 2026 | Diario |
| FSMD · FIDELITY COVINGTON TRUST | 0,14% | 51 459 NS | 31 de julio de 2026 | N-PORT |
| FHEQ · Fidelity Greenwood Street Trust | 0,14% | 18 636 NS | 31 de julio de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,13% | 5 320 SH | 2 de octubre de 2026 | Diario |
| FBUF · Fidelity Greenwood Street Trust | 0,12% | 413 NS | 31 de julio de 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0,11% | 3 600 NS | 31 de julio de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,10% | 224 327 NS | 31 de julio de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,08% | 952 071 SH | 19 de agosto de 2026 | Diario |
| VB · VANGUARD INDEX FUNDS | 0,08% | 1 902 509 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,08% | 211 842 SH | 19 de agosto de 2026 | Diario |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,08% | 6 756 NS | 31 de julio de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,07% | 33 487 NS | 31 de julio de 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,06% | 12 627 NS | 31 de julio de 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,06% | 18 932 SH | 2 de octubre de 2026 | Diario |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 10 557 SH | 19 de agosto de 2026 | Diario |
| ESML · iShares Trust | 0,06% | 22 893 SH | 11 de septiembre de 2026 | Diario |
| WSML · iShares Trust | 0,04% | 4 360 SH | 11 de septiembre de 2026 | Diario |
| TILT · FlexShares Trust | 0,01% | 4 108 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 2 636 335 SH | 19 de agosto de 2026 | Diario |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,01% | 66 405 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 6 819 SH | 19 de agosto de 2026 | Diario |
| ESGV · VANGUARD WORLD FUND | 0,01% | 18 275 SH | 19 de agosto de 2026 | Diario |
| ITOT · iShares Trust | 0,01% | 109 219 SH | 11 de septiembre de 2026 | Diario |
| IWV · iShares Trust | 0,01% | 22 686 SH | 10 de septiembre de 2026 | Diario |
| DFAC · Dimensional ETF Trust | 0,01% | 43 296 NS | 31 de julio de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1 090 NS | 31 de julio de 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 284 NS | 31 de julio de 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 249 NS | 31 de julio de 2026 | N-PORT |
| IJR · iShares Trust | · | 5 061 986 SH | 10 de septiembre de 2026 | Diario |
| IJT · iShares Trust | · | 784 746 SH | 9 de septiembre de 2026 | Diario |
| IWN · iShares Trust | · | 114 658 SH | 11 de septiembre de 2026 | Diario |
| XJR · iShares Trust | · | 11 464 SH | 31 de agosto de 2026 | Diario |
| ISCB · iShares Trust | · | 3 281 SH | 11 de septiembre de 2026 | Diario |
| SMLF · iShares Trust | · | 64 380 SH | 11 de septiembre de 2026 | Diario |
PTCT Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 21 analistas
COMPRA
Objetivo mediano
$101.00
+59,2%
6 28,6%
Compra fuerte
11 52,4%
Compra
3 14,3%
Mantener
1 4,8%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
14 analistas · 2026-10-01Objetivo medio $101.79 +60,4%
← Por Debajo de Todos los Objetivos
Precio Actual $63.46
Mín$70.00
Media$101.79
Máx$137.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| PTCT | $6.19B | 9.8 | 114.5% | 39.4% | -331.5% | · |
| SRRK | $4.78B | -13.4 | · | · | -157.9% | · |
| ORKA | $1.48B | -3.3 | · | · | -25.9% | · |
| COGT | $5.72B | -16.4 | · | · | -83.1% | · |
| MIRM | $4.10B | -168.1 | 54.7% | -4.5% | -8.2% | · |
| TVTX | $3.47B | -131.8 | 110.5% | -5.2% | -34.6% | · |
| ERAS | $1.06B | -8.5 | · | · | -35.7% | · |
| DNTH | $1.78B | -9.8 | -67.3% | -7973.3% | -40.8% | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa
Ninguna señal abierta en este momento — ninguna tarjeta está completada, y eso es honesto.
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Jul 30, 2026